Table 2.
Adjusted hazard ratio (95% confidence interval) of the primary endpoint and all‐cause mortality in relation to baseline biomarkers, by tertiles and by 1 standard deviation increase in log‐transformed biomarkers (n = 1856)
| N participants (n HF/CV death, n all‐cause death) | HF hospitalization or CV death | All‐cause mortality | |
|---|---|---|---|
| NT‐proBNP | |||
| T1 | 610 (119, 124) | Ref. | Ref. |
| T2 | 624 (299, 257) | 2.54 (2.04–3.17) | 1.84 (1.47–2.31) |
| T3 | 619 (416, 388) | 3.96 (3.16–4.98) | 2.98 (2.38–3.74) |
| per 1 SD | 1853 (834, 769) |
1.91(1.74–2.10) P < 0.001 |
1.80 (1.63–1.99) P < 0.001 |
| Troponin T | |||
| T1 | 618 (141, 127) | Ref. | Ref. |
| T2 | 621 (288, 256) | 2.06 (1.66–2.55) | 1.90 (1.51–2.38) |
| T3 | 614 (405, 386) | 3.09 (2.47–3.88) | 3.10 (2.45–3.93) |
| per 1 SD | 1853 (834, 769) |
1.60 (1.48–1.73) P < 0.001 |
1.61 (1.48–1.76) P < 0.001 |
| MR‐proADM | |||
| T1 | 628 (182, 157) | Ref. | Ref. |
| T2 | 620 (269, 251) | 1.30 (1.07–1.59) | 1.40 (1.13–1.73) |
| T3 | 605 (383, 361) | 2.28 (1.83–2.84) | 2.49 (1.96–3.15) |
| per 1 SD | 1853 (834, 769) |
1.53 (1.39–1.68) P < 0.001 |
1.63(1.47–1.80) P < 0.001 |
| Copeptin | |||
| T1 | 619 (187, 175) | Ref. | Ref. |
| T2 | 619 (282, 249) | 1.46 (1.2–1.76) | 1.42 (1.16–1.73) |
| T3 | 615 (365, 345) | 1.66 (1.35–2.04) | 1.78 (1.44–2.20) |
| per 1 SD | 1853 (834, 769) |
1.25 (1.15–1.36) P < 0.001 |
1.31 (1.19–1.43) P < 0.001 |
| Cystatin C | |||
| T1 | 633 (188, 169) | Ref. | Ref. |
| T2 | 613 (278, 253) | 1.36 (1.12–1.66) | 1.28 (1.04–1.57) |
| T3 | 607 (368, 347) | 1.92 (1.55–2.37) | 1.90 (1.52–2.37) |
| per 1 SD | 1853 (834, 769) |
1.36 (1.23–1.50) P < 0.001 |
1.41 (1.27–1.56) P < 0.001 |
| CRP | |||
| T1 | 621 (228, 210) | Ref. | Ref. |
| T2 | 614 (268, 245) | 1.21 (1.01–1.44) | 1.23 (1.02–1.48) |
| T3 | 618 (338, 314) | 1.51 (1.27–1.80) | 1.58 (1.32–1.90) |
| per 1 SD | 1853 (834, 769) |
1.17 (1.09–1.25) P < 0.001 |
1.19 (1.1–1.28) P < 0.001 |
CRP, C‐reactive protein; CV, cardiovascular; HF, heart failure; MR‐proADM, mid‐regional pro‐adrenomedullin; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; SD, standard deviation.
Model: adjusting for region, age, sex, race, body mass index, smoking, systolic and diastolic blood pressure, diabetes, chronic obstructive pulmonary disease, New York Heart Association class, left ventricular ejection fraction, time since diagnosis, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker use, beta‐blocker use, creatinine, HF hospitalization within last 6 months, HF aetiology, stroke, atrial fibrillation/flutter, heart rate.